Real-world outcomes of 54-week vedolizumab therapy and response durability after treatment discontinuation in ulcerative colitis: results from a multicenter prospective POLONEZ study

Real-world outcomes of 54-week vedolizumab therapy and response durability after treatment discontinuation in ulcerative colitis: results from a multicenter prospective POLONEZ study

Background: Vedolizumab is a gut-selective anti-lymphocyte trafficking agent used to treat ulcerative colitis (UC) and Crohn’s disease. Objectives: We aimed to evaluate the effectiveness, safety, and durability of the therapeutic effect of vedolizumab after treatment discontinuation in a real-world...

Full description

Bibliographic Details
Main Authors: Piotr Eder, Maria Kłopocka, Halina Cichoż-Lach, Renata Talar-Wojnarowska, Maria Kopertowska-Majchrzak, Agata Michalak, Rafał Filip, Katarzyna Waszak, Kamila Stawczyk-Eder, Maria Janiak, Krzysztof Skrobot, Ariel Liebert, Hubert Zatorski, Anna Solarska-Półchłopek, Michał Krogulecki, Anna Pękała, Elżbieta Poniewierka, Izabela Smoła, Aleksandra Kaczka, Krzysztof Wojciechowski, Szymon Drygała, Edyta Zagórowicz
Format: Article
Language:English
Published: SAGE Publishing 2023-02-01
Series:Therapeutic Advances in Gastroenterology
Online Access:https://doi.org/10.1177/17562848231151295

Internet

https://doi.org/10.1177/17562848231151295

Similar Items